logo conference-reports

Kongressrapporter

Educational funding by logo MSD Oncology

ESMO 2019 — Controversy — Should therapy be de-escalated in patients with HPV+ oropharyngeal cancer?

Cure rates in oropharyngeal cancer have gone up, but the quality of life in survivors is often compromised by dysphagia and other side effects.
Tjenesten du prøver å få tilgang til er bare tilgjengelig for registrerte brukere. For å fortsette vennligst logg inn eller registrer deg for en gratis konto på Univadis